Normal view MARC view ISBD view

Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy: Possible Modulating Effects of Paracrine Activities of Stem Cells. [Review]

MedStar author(s):

Citation: Journal of the American College of Cardiology. 66(18):2038-47, 2015 Nov 3.PMID: 26516007Institution: MedStar Health Research Institute | MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Cardiomyopathy, Dilated | *Stem Cell Transplantation | Cardiomyopathy, Dilated/et [Etiology] | Cardiomyopathy, Dilated/pp [Physiopathology] | Cardiomyopathy, Dilated/th [Therapy] | Disease Progression | Humans | Myocardial Ischemia/co [Complications] | Outcome Assessment (Health Care) | Stem Cell Transplantation/mt [Methods] | Stem Cell Transplantation/sn [Statistics & Numerical Data] | Ventricular Dysfunction, Left/et [Etiology] | Ventricular Dysfunction, Left/pp [Physiopathology] | Ventricular Dysfunction, Left/th [Therapy]Year: 2015 Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007ISSN:

0735-1097

Name of journal: Journal of the American College of CardiologyAbstract: Over the past 1.5 decades, numerous stem cell trials have been performed in patients with cardiovascular disease. Although encouraging outcome signals have been reported, these have been small, leading to uncertainty as to whether they will translate into significantly improved outcomes. A reassessment of the rationale for the use of stem cells in cardiovascular disease is therefore timely. Such a rationale should include analyses of why previous trials have not produced significant benefit and address whether mechanisms contributing to disease progression might benefit from known activities of stem cells. The present paper provides such a reassessment, focusing on patients with left ventricular systolic dysfunction, either nonischemic or ischemic. We conclude that many mechanisms contributing to progressive left ventricular dysfunction are matched by stem cell activities that could attenuate the myocardial effect of such mechanisms. This suggests that stem cell strategies may improve patient outcomes and justifies further testing. Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.All authors: Bonow RO, Butler J, Cohen I, Epstein SE, Gheorghiade M, Greene SJ, Kelkar AA, Lipinski MJ, Luger D, Quyyumi AA, Schelbert EB, Sun WFiscal year: FY2016Digital Object Identifier:

http://dx.doi.org/10.1016/j.jacc.2015.09.010

Date added to catalog: 2016-05-24

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	26516007	Available		26516007

Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007

Over the past 1.5 decades, numerous stem cell trials have been performed in patients with cardiovascular disease. Although encouraging outcome signals have been reported, these have been small, leading to uncertainty as to whether they will translate into significantly improved outcomes. A reassessment of the rationale for the use of stem cells in cardiovascular disease is therefore timely. Such a rationale should include analyses of why previous trials have not produced significant benefit and address whether mechanisms contributing to disease progression might benefit from known activities of stem cells. The present paper provides such a reassessment, focusing on patients with left ventricular systolic dysfunction, either nonischemic or ischemic. We conclude that many mechanisms contributing to progressive left ventricular dysfunction are matched by stem cell activities that could attenuate the myocardial effect of such mechanisms. This suggests that stem cell strategies may improve patient outcomes and justifies further testing. Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

English